LifeArc is a medical research organization that focuses on translating scientific discoveries into medical treatments and diagnostics. LifeArc has 30 years of experience in antibody humanisation, diagnostics and biomarker development, and drug development.

LifeArc

LifeArc® is a medical research charity making life science life changing, transforming promising life science ideas into medical breakthroughs that change patients’ lives.

We are self-funding and specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures.

We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. This includes Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) and Entyvio® (Crohn’s disease) and a test for antimicrobial resistance. 

Find out more about our work at www.lifearc.org or follow us on LinkedIn or 
Twitter (@lifearc1)


SpringWorks Therapeutics

DJS Antibodies

Eliem Therapeutics

University College London (UCL)

Help shape the future for people who struggle to breathe!

Fill out Asthma + Lung UK's survey and share your thoughts on what research needs to address to improve our understanding of why some people suffer from breathlessness.

As part of our Chronic Respiratory Infection Translational Challenge, we've heard a lot about non-tuberculous mycobacteria pulmonary disease (NTM-PD) and the challenges around diagnosing and monitoring it, especially for those with long-term lung conditions.

Today is World NTM Awareness Day, and our Clinical Development Manager, Rachel Dakin wrote a blog outlining why we feel this is an important area for research and celebrating the recent launch of the new Standards of Care, published by the NTM Network UK: https://lnkd.in/eVi388cF

Rachel added: "The new Standards of Care are a much-needed step in the right direction for people living with NTM disease, including those with underlying respiratory conditions. I hope these Standards are embraced and quickly taken through into implementation so that they start to have a positive impact on the healthcare provision given to people living with this serious disease."

We are seeking 2 dynamic leaders to join our Global Health team in London!

1️⃣ Director, Global Health: https://lnkd.in/dYP_HekF

This role will lead our ambitious global health portfolio, ensuring the successful delivery of strategies for 3 Translational Challenges in antimicrobial resistance, neglected tropical diseases, and emerging viral threats. Collaborate with strategic partners, contribute to our broader global health strategy, act as main science lead, and drive innovation to tackle complex healthcare challenges.

Closing Date: 5 August 2024


2️⃣ Head of Global Health: https://lnkd.in/dxyfBS79

This role will create and execute the global health and associated Translational Challenges direction and strategy and deliver a portfolio of projects. Responsibilities include advocating for strategic initiatives, delivering corporate objectives, resource optimisation, budget allocation, communicating plans to external partners, building an advisory board, engaging with patient and public voices, and leading multi-disciplinary teams.

Closing Date: 5 August 2024


Why work with us?

At LifeArc, you will thrive in an inclusive environment that prioritises health, wellbeing, and professional growth. We also offer exceptional benefits, such as pension employer contributions of up to 12%, private health insurance, and annual leave of 31 days plus bank holidays.

Apply now and discover what you can achieve with us!

We're pleased to see the launch of the NTM Network UK Standards of Care for people living with non-tuberculous mycobacteria (NTM) diseases.

These defined Standards contain measurable indicators of good practice that allow healthcare services to identify areas of strength and opportunities for improvement. Their implementation should ultimately have a significant positive impact on the quality of care and health outcomes for patients – including those living with cystic fibrosis and bronchiectasis, both of which are at greater risk of acquiring NTM infections.

The first patient has been recruited to the FARGO clinical trial – testing a new treatment to improve quality of life for patients living with a rare liver disease, primary sclerosing cholangitis (PSC). The hope is that the new treatment could slow or even reverse the progression of PSC: https://t.ly/xsFcO

LifeArc is co-funding the trial with PSC Support, which is being run by the University of Birmingham at the Birmingham Cancer Research UK Clinical Trials Unit.

The FARGO trial will investigate the potential of faecal microbiota transplantation (FMT) to correct gut microbiome imbalances in PSC patients. If successful this could be a huge breakthrough, as currently there are no treatments for PSC.

"I strongly believe there will be some good data coming out of this trial to benefit everyone in the PSC community" says Rick Dallaway, the first patient to take part after being diagnosed with PSC and inflammatory bowel disease (IBD) in 2016.

PCD Research is hosting a brilliant event, Getting Cilia Moving, at The Francis Crick Institute on 1 October. This industry accelerator day aims to support the development of new treatments for primary ciliary dyskinesia (PCD).

If you work in cystic fibrosis, rare diseases, or ATMPs, grab a ticket now to secure your spot!

ORG:LIFEARC

LifeArc

Analysis Not Available